Oligomycin
WikiDoc Resources for Oligomycin |
Articles |
---|
Most recent articles on Oligomycin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Oligomycin at Clinical Trials.gov Clinical Trials on Oligomycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Oligomycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Oligomycin Discussion groups on Oligomycin Patient Handouts on Oligomycin Directions to Hospitals Treating Oligomycin Risk calculators and risk factors for Oligomycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Oligomycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Oligomycins are macrolides created by Streptomyces that can be poisonous to other organisms.
Function
They have use as antibiotics.
In addition, oligimycin inhibits ATP synthase by blocking its proton channel, which is necessary for oxidative phosphorylation of ADP to ATP (energy production).
Administering oligomycin to an individual can result in very high levels of lactate accumulating in the blood and urine.[citation needed]